This Month in GLP-1 and Face Wellness

Every month we read the GLP-1 news so you do not have to, and write down what matters for people on a wellness or weight journey. Plain language, sources linked, no hype. This is the September 2026 edition.

More people are on a GLP-1 than ever

Gallup reports that 11 percent of U.S. adults now say they take a GLP-1 medication for weight loss, up from 3 percent in 2024. That is a lot of faces changing at once, and a big reason the conversation about GLP-1 and appearance has gone mainstream.

But coverage is getting harder

At the same time, some insurers are pulling back. In Massachusetts, reporting this month from GBH found about 112,000 fewer commercially insured members using a GLP-1 for weight loss between 2025 and early 2026, a drop of roughly half. For many people, how they access these medications is changing, and that means more starts, stops, and switches.

Pills are now a real option

This is the first year with two GLP-1 pills that have FDA approval for weight management. The oral Wegovy pill (semaglutide) was approved in December 2025 and launched in January. Lilly's Foundayo (orforglipron) was approved on April 1, 2026, and can be taken any time of day without food or water restrictions. More options generally means more people starting, and more people on different paths.

The face research is growing

Dermatology is paying attention. A small Vanderbilt imaging study found midface volume loss that tracked with weight lost, mostly in the outer fat layer. In 2026, reviews of GLP-1 effects on skin quality and early work on topical and in-office approaches have followed, and dermatologists report a rise in GLP-1 patients asking about their face. We cover the basics in The GLP-1 Face.

A safety story worth knowing about

Regulators continue to look at a possible link between semaglutide and a rare type of optic nerve damage called NAION. The FDA opened a safety review in 2024. European regulators listed it as a very rare side effect in 2025, and the UK medicines regulator warned of a likely association in February 2026. We are not in a position to weigh in on drug safety. If you notice any change in your vision, contact your prescriber or seek care promptly.

What it means for you

More people, more options, more starts and stops. That makes a steady, consistent record of your own change more valuable, not less. Whatever path you are on, a weekly photo taken the same way, and an honest look at your nights, gives you a line that survives a switch in medication, a pause, or a restart. That is the you-versus-you view VisageAir™ is built around.

See you next month.

Frequently asked questions

Is there a GLP-1 pill for weight loss?

Yes. As of 2026 there are two with FDA approval for weight management: the oral Wegovy pill (semaglutide), approved in December 2025, and Foundayo (orforglipron) from Lilly, approved April 1, 2026, which can be taken any time without food or water restrictions.

How many Americans take GLP-1 drugs?

Gallup reports that 11 percent of U.S. adults say they take a GLP-1 medication for weight loss in 2026, up from 3 percent in 2024.

Do GLP-1 drugs affect vision?

Regulators are reviewing a possible link between semaglutide and a rare optic nerve condition called NAION. European regulators listed it as a very rare side effect in 2025. If you notice any change in your vision, contact your prescriber or seek care promptly.

Matt Cronin Founder of VisageAir. MS in kinesiology, human performance and sports medicine. Started out as a licensed athletic trainer and a certified strength and conditioning specialist through the NSCA.

1. In U.S., GLP-1 Usage Reaches New High. Gallup.
2. Sharp decline in GLP-1 usage in 2026 as insurance companies drop coverage. GBH News, September 17, 2026.
3. Wegovy pill becomes first oral GLP-1 weight-loss drug approved in U.S. Scientific American.
4. FDA approves Lilly's Foundayo (orforglipron). Eli Lilly and Company.
5. Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists. Otolaryngology, Head and Neck Surgery.
6. Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis. PubMed Central.

This article is general wellness and lifestyle education, not medical advice. VisageAir is not a medical device. For questions about a medication, your weight, your sleep, or any health condition, talk with your clinician or prescriber.

---